Results 1 to 10 of about 267,118 (262)

Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia

BMC Medicine, 2021
Background Although there are many clinical and molecular biomarkers in acute myeloid leukemia (AML), the novel and reliable biomarkers are still required to predict the overall survival at the time of disease diagnosis.
Jinghan Wang, Jiajia Pan, Shujuan Huang, Fenglin Li, Jiansong Huang, Xia Li, Qing Ling, Wenle Ye, Yungui Wang, Wenjuan Yu, Jie Jin   +10 more
doaj   +1 more source

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Haematologica, 2023
Chemoimmunotherapy followed by consolidative high-dose therapy with autologous stem cell rescue was a standard upfront treatment for fit patients with mantle cell lymphoma (MCL) in first remission; however, treatment paradigms are evolving in the era of
Zachary D. Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron, Ahmet Dogan, Pamela Drullinsky, John Gerecitano, Paul A. Hamlin, Caleb Ho, Allison Jacob, Ashlee Joseph, Leana Laraque, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Chelsea Mullins, Colette Owens, Gilles Salles, Heiko Schöder, David J. Straus, Anas Younes, Andrew D. Zelenetz, Anita Kumar   +23 more
doaj   +1 more source

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy

Frontiers in Oncology, 2023
BackgroundThe first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy.
Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, Rajat Bansal, Haitham AbdelHakim, Sarah Bromert, Allison Appenfeller, Batool Abu Ghazal, Anurag Singh, Sunil Abhyankar, Siddhartha Ganguly, Siddhartha Ganguly, Joseph McGuirk, Al-Ola Abdallah, Leyla Shune   +14 more
doaj   +1 more source

Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis

Haematologica, 2023
Over the past two decades, there have been significant advances in the treatment of multiple myeloma which has led to an improvement in overall survival.1,2 However, a notable proportion of patients continue to experience early mortality (EM), defined ...
John X. Wei, Aditi Shastri, R. Alejandro Sica, Ioannis Mantzaris, Noah Kornblum, Urvi Shah, Murali Janakiram, Kira Gritsman, Amit Verma, Mendel Goldfinger, Dennis Cooper, Nishi Shah   +11 more
doaj   +1 more source

Elotuzumab as a novel anti-myeloma immunotherapy

Human Vaccines & Immunotherapeutics, 2017
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches.
Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Mary Steinbach, Janet Weidner, Tim Luetkens, Djordje Atanackovic   +5 more
doaj   +1 more source

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors

OncoImmunology, 2017
Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies.
Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Tim Luetkens, Djordje Atanackovic   +3 more
doaj   +1 more source

Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma

Current Oncology, 2023
Mitophagy plays an important role in maintaining mitochondrial homeostasis by clearing damaged mitochondria. Sphingosine kinase 2 (SK2), a type of sphingosine kinase, is an important metabolic enzyme involved in generating sphingosine-1-phosphate.
Jian Wu, Shengjun Fan, Daniel Feinberg, Xiaobei Wang, Shaima Jabbar, Yubin Kang   +5 more
doaj   +1 more source

Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis

Frontiers in Immunology, 2022
BackgroundNatural killer (NK) cells play a vital role in early immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT).MethodsA literature search was performed on PubMed, Cochrane, and Clinical trials.gov through April ...
Muhammad Umair Mushtaq, Moazzam Shahzad, Moazzam Shahzad, Amna Y. Shah, Sibgha Gull Chaudhary, Muhammad U. Zafar, Iqra Anwar, Karun Neupane, Ayesha Khalid, Nausheen Ahmed, Rajat Bansal, Ramesh Balusu, Anurag K. Singh, Sunil H. Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk   +16 more
doaj   +1 more source

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

Haematologica, 2015
For patients who relapse after allogeneic hematopoietic stem cell transplantation while still on immune suppression, there is anecdotal evidence that tapering the immune suppression may result in graft-versus-tumor activity.
Natasha Kekre, Haesook T. Kim, Gita Thanarajasingam, Philippe Armand, Joseph H. Antin, Corey Cutler, Sarah Nikiforow, Vincent T. Ho, John Koreth, Edwin P. Alyea, Robert J. Soiffer   +10 more
doaj   +1 more source

Whole tumor cell vaccines engineered to secrete GM‐CSF (GVAX)

ImmunoMedicine, 2021
Generation of immunity against cancer through vaccination has long been an elusive goal for tumor immunologists. Putative candidates for vaccination targets include oncofetal antigens, viral antigens, neoantigens, and differentiation antigens.
Robert J. Soiffer, Kameron A. Kooshesh, Vincent Ho   +2 more
doaj   +1 more source